drugset / Trial / NCT03051009

Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

NCT03051009

Phase 3 Completed 503 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Demonstrate the safety and tolerability of desmopressin ODT during long-term treatment of subjects with nocturia due to nocturnal polyuria, for up to 1 year

Timeline

Start
2017-01-11
Primary completion
2018-09-11
Completion
2018-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide 25 ug Oral
Subject Desmopressin Peptide 50 ug Oral

Indications

No indication recorded.